Data / Drug companies / Trifluent Pharma, LLC
Trifluent Pharma, LLC: 37 products in the FDA NDC directory, labeler code 73352
Trifluent Pharma, LLC (labeler code 73352) lists 37 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 28 prescription drugs, 9 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 17, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73352
- Products in commercial distribution
- 37
- Packages
- 36
- Finished drugs by generic name
- 23
- Prescription products
- 28
- Over the counter products
- 9
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 1
- Earliest marketing start
- February 17, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 18 | 48.6% |
| Over the counter monograph drugs | 9 | 24.3% |
| Other unapproved drugs | 9 | 24.3% |
| Authorized generics (NDA) | 1 | 2.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 28 | 75.7% |
| Over the counter drugs | 9 | 24.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Levothyroxine and liothyronine | 7 | 2 |
| Lidocaine | 3 | 216 |
| Tizanidine hydrochloride | 2 | 25 |
| Undecylenic acid | 2 | 38 |
| Tolnaftate | 2 | 99 |
| Lactulose | 2 | 18 |
| Fenofibrate | 2 | 56 |
| Lidocaine hydrochloride | 2 | 134 |
| Sodium sulfacetamide and sulfer | 1 | 1 |
| Menthol, unspecified form and methyl salicylate | 1 | 6 |
| Benzalkonium chloride | 1 | 271 |
| Baclofen | 1 | 65 |
| Crotamiton | 1 | 3 |
| Diclofenac potassium | 1 | 42 |
| Dicyclomine hydrochloride | 1 | 50 |
| Dihydroergotamine mesylate | 1 | 13 |
| Econazole nitrate | 1 | 9 |
| Ergotamine tartrate and caffeine | 1 | 3 |
| Lidocaine hci | 1 | 7 |
| Hydrocortisone | 1 | 171 |
| Clotrimazole | 1 | 98 |
| Gabapentin | 1 | 91 |
| Methocarbamol | 1 | 67 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 10 | 27% |
| Cream | 6 | 16.2% |
| Solution | 4 | 10.8% |
| Capsule | 3 | 8.1% |
| Patch | 3 | 8.1% |
| Powder, for solution | 2 | 5.4% |
| Gel | 2 | 5.4% |
| Tablet, coated | 2 | 5.4% |
| Emulsion | 1 | 2.7% |
| Lotion | 1 | 2.7% |
| Spray | 1 | 2.7% |
| Aerosol, foam | 1 | 2.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Gabapentin | 73352-231 | Capsule | Generic drugs (ANDA) | August 17, 2026 |
| Cafergot | 73352-917 | Tablet, film coated | Generic drugs (ANDA) | March 23, 2026 |
| Lidocaine HCI | 73352-204 | Cream | Over the counter monograph drugs | January 9, 2026 |
| EvexiTHROID | 73352-699 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-698 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-697 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-696 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-695 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-694 | Tablet | Other unapproved drugs | October 12, 2025 |
| EvexiTHROID | 73352-693 | Tablet | Other unapproved drugs | October 12, 2025 |
| Sodium Sulfacetamide and Sulfer Emulsion | 73352-750 | Emulsion | Other unapproved drugs | October 4, 2025 |
| Zanaflex | 73352-090 | Capsule | Generic drugs (ANDA) | September 16, 2025 |
| Tizanidine Hydrochloride | 73352-089 | Capsule | Generic drugs (ANDA) | September 16, 2025 |
| Lactulose | 73352-905 | Powder, for solution | Generic drugs (ANDA) | September 13, 2025 |
| Lactulose | 73352-900 | Powder, for solution | Generic drugs (ANDA) | September 13, 2025 |
| Econazole Nitrate | 73352-100 | Aerosol, foam | Authorized generics (NDA) | September 13, 2025 |
| Fenofibrate | 73352-102 | Tablet | Generic drugs (ANDA) | August 12, 2025 |
| Fenofibrate | 73352-101 | Tablet | Generic drugs (ANDA) | August 12, 2025 |
| Dicyclomine hydrochloride | 73352-119 | Tablet | Generic drugs (ANDA) | July 14, 2025 |
| Dihydroergotamine mesylate | 73352-096 | Spray | Generic drugs (ANDA) | July 8, 2025 |
| Baclofen | 73352-103 | Solution | Generic drugs (ANDA) | June 5, 2025 |
| Pruradik | 73352-051 | Lotion | Generic drugs (ANDA) | June 2, 2025 |
| Methocarbamol | 73352-510 | Tablet, coated | Generic drugs (ANDA) | February 10, 2025 |
| Hydrocortisone | 73352-455 | Solution | Generic drugs (ANDA) | November 22, 2024 |
| Tridacaine XL | 73352-845 | Patch | Generic drugs (ANDA) | September 20, 2024 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.